Listed by the USPTO as CHANG, KYUNG SOOK
Tech Center 3700 • Art Units: 1613 1615 1616 1617 1628 1672 3786
This examiner grants 60% of resolved cases
CHANG, KYUNG SOOK works in tech center 3700 and art unit 1613, with 807 resolved cases. The profile shows a 60.5% allowance rate and a median of 990 days to allowance. This record presents a lower allowance outcome than profiles centered on more frequent allowances, while the median timeline remains substantial for portfolio management.
Interviews are associated with a 40.8% lift in the allowance rate, making examiner dialogue a significant strategic consideration. The listed companies are The Brigham and Women's Hospital, Procter & Gamble, and DSM IP Assets. The leading firms are FisherBroyles, FOLEY HOAG, and NIXON & VANDERHYE. Counsel may benefit from pairing focused interviews with claim amendments that directly address the examiner's stated issues.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18909342 | RHEOLOGICAL SOLID COMPOSITION FOR USE IN PERSONAL CARE COMPOSITIONS | Non-Final OA | The Procter & Gamble Company |
| 18909337 | RHEOLOGICAL SOLID COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18755888 | Oral Care Compositions Comprising Hops Beta Acids | Final Rejection | The Procter & Gamble Company |
| 18577485 | SELF-PROPELLED PHARMACEUTICAL DELIVERY CAPSULES | Final Rejection | Cochlear Limited |
| 17593514 | MOUSSE PRODUCTS, METHODS AND DEVICES | Final Rejection | Honeywell International Inc. |
| 18873973 | SUNSCREEN COMPOSITION FOR LACTOBACILLUS AND S. EPIDERMIDIS PROTECTION ON SKIN | Non-Final OA | DSM IP Assets B.V. |
| 18874006 | SUNSCREEN COMPOSITION FOR LACTOBACILLUS AND S. EPIDERMIDIS PROTECTION ON SKIN | Non-Final OA | DSM IP Assets B.V. |
| 18878955 | Emulsion With a Dialkyl Carbonate, Coconut Oil Esters, a Volatile Hydrocarbon-Based Oil and a Polyethylene Glycol Dipolyhydroxystearate Containing 30 Mol of Ethylene Oxide | Non-Final OA | L'OREAL |
| 18543860 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, SEMI-CRYSTALLINE POLYMER AND SCLEROGLUCAN GUM | Non-Final OA | L'OREAL |
| 18506757 | CONTACT LENS FOR PHOTODYNAMIC INACTIVATION OF GERMS, PRODUCT AND METHOD OF TREATING FUNGAL KERATITIS BY APPLYING THE SAME | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18729995 | ORAL DOSAGE FORMS OF A THERAPEUTICALLY ACTIVE ACID-LABILE SALT AND METHODS AND USES RELATED THERETO | Non-Final OA | UMC Utrecht Holding B.V. |
| 18879427 | COSMETIC COMPOSITION | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 19083010 | HERBICIDAL COMPOSITION | Non-Final OA | NOURYON CHEMICALS INTERNATIONAL B.V. |
| 18874081 | Lipid Nanoparticles and Production Method for Same | Non-Final OA | Kewpie Corporation |
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17928003 | 3-HYDROXYBUTYRIC-ACID-CONTAINING OIL AND FAT COMPOSITION | Non-Final OA | OSAKA GAS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy60.5% of resolved applications examined by Kyung Sook Chang were allowed (807 resolved cases), compared with 34.0% across Art Unit 1613 over the last five years.
This examiner's interview lift is +40.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kyung Sook Chang took 990 days on average from filing to allowance.
Kyung Sook Chang examines applications in Art Unit 1613 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
